Nevigremon - antibacterial drug used in the treatment of infections of the genitourinary system.
Release form and composition
Nevigramon produced in the form of capsules: hard gelatin, opaque, with a yellow body and a lid, size No. 0; the contents of the capsules - powder from white with a yellowish tinge to white (56 pcs. in polystyrene bottles, 1 bottle in a carton box).
The composition of 1 capsule includes:
- Active ingredient: nalidixic acid - 500 mg;
- Auxiliary components: colloidal silicon dioxide - 19 mg; stearic acid - 11 mg;
- Capsule shell: quinoline dye yellow (E104) - 0.75%; titanium dioxide (E171) - 2%; the dye sunsets sunset yellow (E110) - 0,0059%; gelatin - up to 100%.
Indications for use
- Infections caused by microorganisms sensitive to the action of the active substance, including infections of the gastrointestinal tract, cholecystitis, pyelonephritis, urethritis, cystitis, prostatitis (treatment);
- Infections during operations on the ureters, kidneys, bladder (prevention).
- Parkinson's disease;
- Deficiency of glucose-6-phosphate dehydrogenase;
- Atherosclerosis of cerebral vessels (in severe form);
- Hepatic and / or renal failure;
- Age up to 12 years;
- First trimester of pregnancy and lactation;
- Hypersensitivity to the drug.
Children 12-18 years of age Nevigrammon should be prescribed with caution.
Dosing and Administration
Nevigrammon taken orally, preferably 1 hour before meals.
The following dosing regimen is recommended:
- Adults, including elderly patients: 4 g per day (4 capsules 4 times a day). The duration of therapy is not less than 7 days. If you need a longer treatment, a single dose should be reduced by 2 times, without changing the frequency of taking the drug;
- Children from 12 years old (weighing more than 40 kg): 50 mg / kg per day. The multiplicity of reception - 3-4 times a day.
The following side effects may develop during the use of Nevigramone:
- Central nervous system: drowsiness, headaches, weakness, dizziness. There are rare reports of the development of toxic psychosis, increased intracranial pressure or seizures (as a rule, in the presence of predisposing diseases - epilepsy, cerebral arteriosclerosis). Selected cases of paralysis of the sixth cranial nerve are also described. The mechanism of these disorders has not been investigated, however, usually these effects disappear independently after discontinuation of therapy
- Gastrointestinal: nausea, epigastric pain, diarrhea, vomiting;
- Organ of vision: impaired color perception and vision (in the form of diplopia, decrease in visual acuity, difficulty in focusing). As a rule, these disorders quickly disappear after dose reduction or cancellation of Neugramon
- Skin reactions: photosensitivity reactions in the form of redness and blistering of the skin, which completely disappear during the period from 14 days to 2 months after the cancellation of Nevigramone. In some cases, with minor damage to the skin surface or under the influence of sunlight, bubbles may reappear within 3 months after drug withdrawal;
- Allergic reactions: itching, rash, eosinophilia, urticaria, arthralgia with swelling of joints and stiffness; rarely - anaphylactic shock, angioedema, anaphylactoid reactions;
- Other: rarely - paresthesia, cholestasis, thrombocytopenia, metabolic acidosis, hemolytic anemia, or leukopenia, sometimes accompanied by a deficiency of glucose-6-phosphate dehydrogenase.
If arthralgia develops, Nevigrammon should be canceled.
Exposure to direct sunlight should be avoided during therapy, and therapy is interrupted when photosensitivity occurs. Nevigrammon should also be discontinued if symptoms of psychosis, increased intracranial pressure, or other toxic manifestations occur.
Bacterial resistance to Nevigrammon develops, usually within the first 48 hours. Cross-resistance was observed between nalidixic acid and other quinolone derivatives (for example, oxolinic acid, cynoxacin).
During the urine analysis using methods based on copper recovery (for example, using Fehling or Benedict solutions), it is possible to obtain a false positive reaction to glucose. Therefore, during therapy, it is recommended to use specific glucose oxidase methods.
False values can also be obtained during the determination of 17-keto steroids and ketogenic steroids in the urine when conducting analyzes based on the measurement of vanillyl alindic acid in the urine. In these cases, the Porter-Zilber test can be used for 17-hydroxycorticosteroids.
During the use of Nevigramon, care must be taken when driving and performing potentially hazardous types of work that require a patient’s attention concentration and quick psychomotor reactions.
When combined with Nevigramone some drugs may experience the following effects:
- Oral anticoagulants (warfarin, bis-hydroxycoumarin): increase their effect (if necessary, combination therapy should be monitored prothrombin time or the international normalization index (INR), you may also need to change the dose of anticoagulant);
- Other antibacterial compounds, in particular tetracycline, nitrofurantoin, chloramphenicol: may suppress the action of nalidixic acid;
- Probenecid: suppressing the secretion of nalidixic acid in the renal tubules, reducing its effectiveness against infections of the urogenital system and increasing the likelihood of systemic side effects;
- Melphalan: development of gastrointestinal toxicity.
Terms and conditions of storage
Keep out of reach of children at temperature up to 25 ° C.
Shelf life - 5 years.